Literature DB >> 2981605

Radiation therapy for pineal and suprasellar germ cell tumors.

T A Rich, J R Cassady, R D Strand, K R Winston.   

Abstract

Radiation therapy (XRT) was used in the treatment of 25 patients with tumors of the pineal and suprasellar locations. A tissue diagnosis was obtained before XRT in 5 patients, and 20 were irradiated without histologic verification. The overall survival rate is 80% (76% with no evidence of disease [NED]). Megavoltage XRT was delivered to the entire neuraxis in 22 patients, and 86% (19/22) are alive from 4 to 88 months (median, 30 months) after treatment. In two of three patients treated only to local fields, tumor recurred in the spine; both are dead of disease. Biopsy-proven germinomas and multiple midline tumors responded favorably to XRT, whereas solitary pineal tumors and teratomas with marker positivity (human chorionic gonadotropin, alpha-fetoprotein) did not respond as well. The endocrinologic presentation, tumor marker status, and early response to radiation measured on computed tomography are useful means for selecting patients for radiation therapy.

Entities:  

Mesh:

Year:  1985        PMID: 2981605     DOI: 10.1002/1097-0142(19850301)55:5<932::aid-cncr2820550504>3.0.co;2-h

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  19 in total

1.  Primary intracranial germ cell tumours (GCT) fail to highlight important aspects of the current management of this condition.

Authors:  S Senan
Journal:  J Neurooncol       Date:  1992-11       Impact factor: 4.130

2.  Tumours in the pineal and supra-sellar region. A review of clinical manifestations and managements.

Authors:  K Watne
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130

3.  Complete disappearance of giant intracranial germinoma after irradiation.

Authors:  N G Rainov; H J Holzhausen; W Burkert
Journal:  Neurosurg Rev       Date:  1995       Impact factor: 3.042

4.  Intracranial germ cell tumors: a multi-institutional experience from three tertiary care centers in India.

Authors:  Aanchal Kakkar; Ahitgani Biswas; Nikhil Kalyani; Uttara Chatterjee; Vaishali Suri; Mehar C Sharma; Nishant Goyal; Bhawani S Sharma; Supriya Mallick; Pramod K Julka; Girish Chinnaswamy; Brijesh Arora; Epari Sridhar; Sandip Chatterjee; Rakesh Jalali; Chitra Sarkar
Journal:  Childs Nerv Syst       Date:  2016-07-30       Impact factor: 1.475

5.  Computed tomography of germinomas in basal ganglia and thalamus.

Authors:  T Soejima; I Takeshita; H Yamamoto; Y Tsukamoto; M Fukui; S Matsuoka
Journal:  Neuroradiology       Date:  1987       Impact factor: 2.804

6.  Cisplatin-based chemotherapy in primary central nervous system germ cell tumors.

Authors:  S R Patel; J C Buckner; W A Smithson; B W Scheithauer; R V Groover
Journal:  J Neurooncol       Date:  1992-01       Impact factor: 4.130

7.  Improved outcome of central nervous system germ cell tumors: implications for the role of risk-adapted intensive chemotherapy.

Authors:  Keon Hee Yoo; Soo Hyun Lee; Jeehun Lee; Ki Woong Sung; Hye Lim Jung; Hong Hoe Koo; Do Hoon Lim; Jong Hyun Kim; Hyung Jin Shin
Journal:  J Korean Med Sci       Date:  2010-02-17       Impact factor: 2.153

8.  Extended focal radiotherapy of 30 Gy alone for intracranial synchronous bifocal germinoma: a single institute experience.

Authors:  Pin-I Huang; Yi-Wei Chen; Tai-Tong Wong; Yi-Yen Lee; Kai-Ping Chang; Wan-Yuo Guo; Feng-Chi Chang; Muh-Lii Liang; Hsin-Hung Chen; Shi-Hwa Chiou; Sang-Hue Yen
Journal:  Childs Nerv Syst       Date:  2008-06-25       Impact factor: 1.475

9.  Pineal region tumours of childhood.

Authors:  F J Schulte; H D Herrmann; D Müller; H Franke; W Saeger; F W Spaar; S Bartels
Journal:  Eur J Pediatr       Date:  1987-05       Impact factor: 3.183

10.  Treatment strategy for intracranial primary pure germinoma.

Authors:  Kyu-Won Shim; Eun Kyung Park; Yoon-Ho Lee; Chang-Ok Suh; Jaeho Cho; Joong-Uhn Choi; Dong-Seok Kim
Journal:  Childs Nerv Syst       Date:  2012-09-11       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.